A clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. We are developing our lead product candidate, ADG20, for the treatment and prevention of coronavirus disease 2019, or COVID-19, the disease caused by the virus SARS-CoV-2 and its variants.
Lead Underwriter
Guggenheim Securities, LLC, Jefferies LLC, Morgan Stanley & Co. LLC, Stifel Nicolaus & Company, Incorporated
